Navigation Links
Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference

THOUSAND OAKS, Calif., March 3, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) will present at the Cowen and Company 31st Annual Healthcare Conference on Tuesday, March 8, 2011 at the Boston Marriott Copley Place, Boston, Mass., beginning at 8:45 a.m. Eastern Time.  James Daly, Amgen's Senior Vice President of North American Commercial Operations, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website,, under Investors.

About AmgenAmgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit Amgen, Thousand OaksDavid Polk, 805-447-4613 (media)Arvind Sood, 805-447-1060 (investors)(Logo:


Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
2. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
3. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
4. Call for Applications: The Amgen Award for Science Teaching Excellence
5. Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits
6. Amgen to Provide Testimony at FDA Hearing on Biosimilars
7. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
8. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
9. Array BioPharma and Amgen Partner in Type 2 Diabetes
10. Amgen to Present at Lazard Capital Healthcare Conference
11. Amgen Announces Webcast of 2009 Third Quarter Financial Results
Post Your Comments:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") ( ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):